StockData
LeonaBio, Inc. logo

LeonaBio, Inc. (LONA) company profile

LONANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$2.65−0.11 (-3.99%)

Close on Nov 18, 2026Market cap $24.97MP/E –Yield –

About LeonaBio

Biological Products, (No Diagnostic Substances), SIC 2836

Athira Pharma is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for diseases with substantial unmet medical needs, primarily targeting neurological disorders and treatment-resistant oncology. Its lead oncology candidate is lasofoxifene, an orally bioavailable selective estrogen receptor modulator in Phase 3 clinical evaluation for patients with ESR1-mutated metastatic breast cancer. In neurology, the company develops ATH-1105, an orally administered small-molecule positive modulator of the hepatocyte growth factor system being prepared for Phase 2 clinical trials in individuals with amyotrophic lateral sclerosis. The company additionally explores early-stage pipeline assets, such as ATH-1020, to improve neuronal function. Target patient populations consist of individuals living with neurodegenerative conditions and advanced breast cancer.

Athira Pharma conducts global clinical development operations across the United States and Europe, excluding Asia and parts of the Middle East for its in-licensed oncology program. The company is actively pursuing registrational trials enrolling hundreds of study participants. The provided report does not disclose its corporate headquarters location or founding details.

Summary of the business section of LeonaBio's latest annual report, written by StockData.

Company profile

Company

Legal name
LeonaBio, Inc.
Headquarters
Bothell, WA
Address
18706 North Creek Parkway, Suite 104 98011
Phone
(425) 620-8501
Employees
19, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Seattle, Washington

Stock & identifiers

Ticker
LONA
Former tickers
ATHA until Jan 9, 2026
Exchange
Nasdaq
IPO date
Sep 18, 2020
Shares outstanding
9M, Aug 4, 2026
Public float
$9.90M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-10 reverse, Sep 18, 2025
SEC CIK
1620463
CUSIP
04746L203
ISIN
US04746L2034
FIGI
BBG00C77LX40
Share class FIGI
BBG00C77LXM0
LEI
529900CSS4S4X8VY5C81
EIN
45-3368487

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Mark James LittonPRESIDENT and CEO, Director59,894
Robert RenningerCHIEF FINANCIAL OFFICER15,851
Mark WorthingtonGENERAL COUNSEL and CCO18,376
Martin Javier SanCHIEF MEDICAL OFFICER15,887
Kevin ChurchCHIEF SCIENTIFIC OFFICER25,178
Life Sciences Master Fund Ltd PerceptiveDirector3,114,805
Advisors Llc PerceptiveDirector776,648
Joseph EdelmanDirector5,402,964
Natalie C. HollesDirector–
Grant PickeringDirector25,783
Michael A. PanzaraDirector0
Kelly A. RomanoDirector80,715
James A. JohnsonDirector5,000
Barbara KosaczDirector0
Fred CalloriDirector–
Peter B. SilvermanDirector–
John M. Fluke JrDirector148,615
Perceptive Xontogeny Venture Fund II, LPDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$1.42M$1.95M$770.81K$31000–
FY2024$3.18M$1.15M$1.43M$24000–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsOtherTotalvs. prior year
Mark Litton
President and Chief Executive Officer
$625.00K$171.88K$83.72K$518.14K$25.09K$1.42M-55%
Javier San Martin
Chief Medical Officer
$500.00K$100.00K$27.91K$182.14K$85$810.13K–
Mark Worthington
General Counsel, Chief Compliance Officer and Corporate Secretary
$450.00K$90.00K$21.54K$140.60K$29.34K$731.48K-45%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Sep 18, 2020
Offer price
$17.00
Securities offered
12,000,000
Gross proceeds
$204.00M
Exchange
Nasdaq
First trading day
Sep 18, 2020
First-day close
$17.11+0.6%
Lock-up ends (est.)
Mar 17, 2021

“The initial public offering price is $17.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 19 employees, all of whom were full-time and ten of whom were engaged in research and development activities.”

Corporate history

Events identified from SEC filings

DateEventDetails
Mar 31, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 8, 2026Name changeName changed from Athira Pharma, Inc. to LeonaBio, Inc.
Apr 16, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 18, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 18, 2020IPOInitial public offering priced (424B4 prospectus)
Sep 9, 2020ListingRegistration of securities on an exchange (Form 8-A)
Jan 23, 2019Name changeName changed from M3 Biotechnology, Inc. to Athira Pharma, Inc.

See a number that looks wrong?